Cytosorbents Corporation · NASDAQ:CTSO
Cytosorbents — Investor Presentation (April 2026)
30 slides from Cytosorbents's investor presentation, April 2026
Slide 1: Investor Presentation April 2026
NASDAQ: CTSO Investor Presentation April 2026 1 |
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical, Inc and CytoSorbents Europe GmbH that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actu
Slide 3: Regulatory Disclaimer
Regulatory Disclaimer CytoSorb • CE Marked in Europe for the following APPROVED Indications for Use: • Cytokine Removal • Bilirubin and Myoglobin Removal • Ticagrelor and Rivaroxaban removal during cardiothoracic surgery • CytoSorb is NOT yet cleared/approved by the FDA or Health Canada • CytoSorb r
Slide 4: CytoSorbents at a Glance
CytoSorbents at a Glance • Platform blood purification technology to remove toxins and harmful substances from the blood • High margin “razorblade” that we manufacture in the U.S. and is “plug and play” into existing hospital blood pumps CytoSorb • Used to treat life-threatening conditions in the IC
Slide 5: The Power of the Bead
The Power of the Bead Hemocompatible, highly porous polymer bead platform technology that act like tiny sponges to remove harmful substances from blood by pore capture, adsorption, and concentration • Excellent removal of a broad range of substances from whole blood and plasma • Solid state porous p
Slide 6: Products are "Plug and Play" Compatible
Products are “Plug and Play” Compatible Compatible with Existing Blood Pump Infrastructure In Hospitals Today Dialysis or CRRT Hemoperfusion (Continuous Renal Replacement Therapy) (Standalone Treatment) ECMO CPB (Extracorporeal Membrane Oxygenation) (Cardiopulmonary Bypass) 6 | CytoSorbents Confiden
Slide 7: CytoSorb
CytoSorb Our Core Business CytoSorb is E.U. CE Mark approved but not yet cleared or approved in the U.S./Canada 7 |
Slide 8: CytoSorb is Expanding the Dimension of Blood Purification
CytoSorb is Expanding the Dimension of Blood Purification CytoSorb is a powerful blood purification technology CE-mark approved in the E.U. to reduce cytokines, bilirubin, myoglobin, and blood thinners like ticagrelor & rivaroxaban. It can remove many substances that dialysis cannot. CytoSorb is des
Slide 9: Uncontrolled Massive Inflammation - the Heart of Critical Illness
Uncontrolled Massive Inflammation - the Heart of Critical Illness • Acute inflammation is the body’s mechanism to fight injury and infection • However, severe inflammation, driven by cytokine storm, can cause a chain reaction of problems that can end in organ failure and death CAPILLARY IMMUNE SHOCK
Slide 10: Targets Deadly Conditions That Afflict Millions of People
Targets Deadly Conditions That Afflict Millions of People Critical Care Cardiothoracic Surgery Removes the “fuel to the fire” of massive Reduces inflammation and blood thinners, uncontrolled inflammation that is often targeting reduction in complications of cardiac associated with organ failure and
Slide 11: CytoSorb Has Much Larger ICU Opportunity than Dialysis
CytoSorb Has Much Larger ICU Opportunity than Dialysis Sepsis, Septic Shock, Liver Cytokine storm/ Other Shock Cytokine release Pancreatitis failure syndrome Infectious diseases Post-surgical Neuroinflammation (flu, COVID-19, other) Burn injury complications Organ transplant Acute Respiratory High r
Slide 12: CytoSorb Supported by a Wealth of Clinical Data
CytoSorb Supported by a Wealth of Clinical Data 12 |
Slide 13: Plan to Leverage Many New Publications
Plan to Leverage Many New Publications • A lot of publication activity has been highlighted in recent press releases in many of our focus areas including sepsis and septic shock, acute liver failure, cardiogenic shock, rhabdomyolysis, heart transplantation, endocarditis, and blood thinner removal •
Slide 14: CytoSorbents is Leading a New Era in Sepsis Treatment
CytoSorbents is Leading a New Era in Sepsis Treatment For more than a decade, CytoSorbents has collaborated with clinicians and scientists around the world to advance the treatment of sepsis and septic shock by complementing traditional antibiotics with the broad-spectrum capability of CytoSorb Cyto
Slide 15: Turning the Tide of Sepsis and Septic Shock
Turning the Tide of Sepsis and Septic Shock: Real World Insights with CytoSorb September 10, 2025 Link to webinar replay: https://cyto.news/webinar-sepsis/sep10 15 |
Slide 16: Extracorporeal Liver Support with CytoSorb
Extracorporeal Liver Support with CytoSorb CytoSorb is E.U. approved to remove bilirubin in patients with acute liver disease and is being used today as an advanced liver support therapy • Reduces bilirubin and bile acids more effectively and with greater capacity than other therapies • Specializes
Slide 17: CytoSorb Efficiently Removes Myoglobin in Rhabdomyolysis
CytoSorb Efficiently Removes Myoglobin in Rhabdomyolysis • Rhabdomyolysis is a serious, potentially life-threatening complication of trauma or ischemic injury (e.g. post- tourniquet syndrome, compartment syndrome, other critical illnesses such as sepsis) involving the rapid breakdown of damaged skel
Slide 18: The Opportunity of DrugSorb-ATR
The Opportunity of DrugSorb-ATR is an investigational device that is not yet cleared/approved by FDA, Health 18 | Canada, or by any other Global Regulatory Agency and is not commercially available for sale
Slide 19: Blood Thinners Can Cause Serious Perioperative Bleeding
Blood Thinners Can Cause Serious Perioperative Bleeding • Millions of people are on blood thinners to reduce their risk of heart attack and stroke • However, if urgent, unscheduled surgery is required, they risk serious perioperative bleeding • For example, acute heart attack patients commonly recei
Slide 20: Brilinta and the Use Case for DrugSorb-ATR
® Brilinta and the Use Case for 5 - 10% will need open heart surgery The ultimate goal of DrugSorb-ATR is to allow patients to get the critical surgery they need without delay while reducing or preventing bleeding X X XX X complications 20 | DrugSorb-ATR is an investigational device in the U.S. and
Slide 21: Seeking De Novo Authorization for DrugSorb-ATR
Seeking De Novo Authorization for DrugSorb-ATR • U.S. & Canadian randomized controlled pivotal STAR-T trial established DrugSorb-ATR as a De Novo 510(k) eligible device, DrugSorb-ATR must show that its probable benefits outweigh its probable risks to gain market clearance • Our initial De Novo submi
Slide 22: FDA Regulatory Update
FDA Regulatory Update • In late-January 2026, we held a formal Pre-Submission Meeting with FDA and continue to actively engage with FDA to clarify and confirm the requirements for a new De Novo submission • As these interactive discussions are ongoing, we expect to provide an update on the anticipat
Slide 23: Meanwhile, STAR-T RCT Is Now Published In Press
Meanwhile, STAR-T RCT Is Now Published In Press The Journal of Thoracic and Cardiovascular Surgery is the leading U.S. peer-reviewed cardiothoracic surgery journal 23 | DrugSorb-ATR is an investigational device in the U.S. and Canada and not yet cleared/approved
Slide 24: As Real World Evidence Builds
As Real World Evidence Builds 24 | Brilinta® is a trademark of AstraZeneca DrugSorb-ATR is an investigational device in the U.S. and Canada and not yet cleared/approved
Slide 25: Financial Performance
25 Financial Performance CytoSorbents.
Slide 26: CytoSorb Commercialization Focus
CytoSorb Commercialization Focus • We sell CytoSorb in more than 70 countries worldwide with more than 300,000 treatments to date • Sell Direct in Germany and 9 other countries & through Distributors and partners in the remainder Estimated Revenue By Market Revenue By Geography Other Critical Care:
Slide 27: Targeting Continued Annual Revenue Growth
Targeting Continued Annual Revenue Growth Annual Product Sales Revenue $45.0 • 2025 full year revenue was $37.1M, +4% vs $40.0 $39.5M $40.1M $37.1M $35.6M in 2024 $6.3 $9.4 $35.6M $37.1 $35.0 $35.6 $33.8 $31.1M* $30.0 $29.4M* $31.1 Gross Margins $30.1 $29.1 $ IN MILLONS $25.0 • Q4 2025: 74 vs. 70% i
Slide 28: Driving to Cash Flow Breakeven
Driving to Cash Flow Breakeven • Ended 2025 with $7.8 million in cash and cash equivalents • Implemented a previously announced strategic workforce and cost reduction program in Q4 2025, with expectation of a significantly decreased cash burn in the first half of 2026. • Workforce reduction of >10%
Slide 29: A Clear and Compelling Value Proposition
A Clear and Compelling Value Proposition We believe we have a sound plan to build and maximize shareholder value CytoSorb is an established, international core business in critical care and cardiac surgery with $37.1M in high margin product sales and an excellent “razorblade” business model with exp
Slide 30: CytoSorbents Corporation
CytoSorbents Corporation NASDAQ: CTSO Company Contact: Dr. Phillip Chan pchan@cytosorbents.com www.cytosorbents.com 30